Julie Autmizguine

Julie Autmizguine

Auto-generated profile, based on publicly available information

Julie Autmizguine

Department of Pharmacology and Physiology, Université de Montréal, Montreal, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
BFBénédicte Franck
Bénédicte Franck
JAJulie Autmizguine
Julie Autmizguine
PMPierre Marquet
Pierre Marquet
POPhilippe Ovetchkine
Philippe Ovetchkine
JWJean-Baptiste Woillard
Jean-Baptiste Woillard

1 March 2015 in Clinics in Perinatology
Verified
Journal Article
Closed access
ABAna C. Blanchard
Ana C. Blanchard
CQCaroline Quach
Caroline Quach
JAJulie Autmizguine
Julie Autmizguine

1 January 2019 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
CTCéline Thibault
Céline Thibault
NKNastya PharmD Kassir
Nastya PharmD Kassir
IGIsabelle Bpharm Goyer
Isabelle Bpharm Goyer
YTYves Théorêt
Yves Théorêt
CLCatherine Litalien
Catherine Litalien
JAJulie Md Autmizguine
Julie Md Autmizguine
Background: The emergence of coagulase-negative staphylococci with reduced vancomycin susceptibility in some neonatal intensive care units has resulted in an increase of linezolid use. Linezolid pharmacokinetics (PK) and safety in premature infants still need to be better established. Methods: This was a retrospective PK study. All infants who received intravenous linezolid and had linezolid plasma concentrations per standard of care were included. Linezolid concentrations were measured by high performance liquid chromatography. A population PK model was developed using nonlinear mixed effects modeling. Optimal dosing was determined based on achievement of the surrogate pharmacodynamics target for efficacy: a ratio of the area under the concentration–time curve to minimum inhibitory concentration >80. We assessed the occurrence of thrombocytopenia and lactic acidosis in relation with drug exposure. Results: A total of 78 plasma concentrations were collected from 26 infants, with a median postnatal age (PNA) of 24 days (8–88) and weight of 1423 g (810–3256). A 1-compartment model described linezolid data well. The final model included PNA and weight on clearance and weight on volume of distribution. Considering an MIC90 of 1 mg/L, all infants reached an area under the concentration–time curve/minimum inhibitory concentration > 80. Although thrombocytopenia and hyperlactatemia occurred frequently, they were not sustained and were not considered related to linezolid. Conclusion: and was well tolerated in critically ill premature infants. PNA was the main determinant of clearance.

29 December 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
BFBénédicte Franck
Bénédicte Franck
JWJean-Baptiste Woillard
Jean-Baptiste Woillard
YTYves Théorêt
Yves Théorêt
HBHenrique Bittencourt
Henrique Bittencourt
EDEmile Demers
Emile Demers
JAJulie Autmizguine
Julie Autmizguine

1 December 2013 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JAJulie Autmizguine
Julie Autmizguine
KWKevin M. Watt
Kevin M. Watt
YTYves Théorêt
Yves Théorêt
NKNastya Kassir
Nastya Kassir
CLC. Laferrière
C. Laferrière
POPhilippe Ovetchkine
Philippe Ovetchkine
Background: Osteoarticular infections lead to significant morbidity in children. Cephalexin has in vitro activity against methicillin-susceptible Staphylococcus aureus, a predominant pathogen in osteoarticular infection. However, cephalexin pharmacokinetics (PK) and pharmacodynamics (PD) are poorly described in children. This study described cephalexin PK in children treated for osteoarticular infection and assessed the proportion of children achieving surrogate PK/PD target for efficacy in methicillin-susceptible S. aureus infection. Methods: Children with osteoarticular infection, 1 to 18 years of age, were eligible for this study if they were receiving oral cephalexin per standard of care. PK plasma samples were collected at specified times after multiple doses. PK parameters were estimated using noncompartmental analysis. PK/PD target for efficacy was calculated using the child’s PK parameters, minimum inhibitory concentration (MIC) of the isolate when available and previously described MIC of 2 and 4 mg/L. Results: Twelve children were enrolled and PK profiles were obtained from 11 of them. Median age was 7 years, and median cephalexin dose was 40 mg/kg/dose every 8 hours. Median apparent oral clearance, apparent oral volume of distribution and elimination half-life (T1/2) were 0.29 L/h/kg, 0.44 L/kg and 1.1 h, respectively. Time above MIC (T>MIC) was greater than 40% of the dosing interval in 100%, 90% and 80% of the children when MICs were 0.25, 2 and 4 mg/L, respectively. Conclusions: Oral cephalexin achieved optimal plasma exposure and was well tolerated in children with osteoarticular infection. Correlation between osteoarticular infection clinical outcome and PK/PD parameters needs further evaluation.

1 November 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
CTCéline Thibault
Céline Thibault
JLJean Lavigne
Jean Lavigne
CLCatherine Litalien
Catherine Litalien
NKNastya Kassir
Nastya Kassir
YTYves Théorêt
Yves Théorêt
JAJulie Autmizguine
Julie Autmizguine
Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children ranging in age from 2 months to 6 years from various clinical subpopulations.